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I.  General Information 
 
Anhydrous THF was purified and dried using a solvent-purification system that contained 
activated alumina.  The following reagents and solvents were purchased and used as received: 
lithium metal (granular, 4-10 mesh particle size, 99%; Aldrich), zinc chloride (≥98%; Aldrich), 
dimethylphenylchlorosilane (TCI), chloro(methyl)diphenylsilane (Aldrich), 
chlorotriphenylsilane (Acros), NiBr2·diglyme (Aldrich), dimethylacetamide (≥99%, over 
molecular sieves; Aldrich), triphenylphosphine (Aldrich), bromine (Aldrich), imidazole 
(Aldrich), LiBr (≥99%; Aldrich), and N-Boc-4-bromopiperidine (Aldrich).  All other alkyl 
bromides were prepared from the corresponding alcohols according to General Procedure A or 
B. 
1H and 13C NMR spectroscopic data were collected on a Varian 500 MHz spectrometer at 
ambient temperature.  GC analyses were obtained on an Agilent 6890 Series GC system with a 
DB-1 column (length 30 m, internal diameter 0.25 mm). 
 
 
II.  Preparation of Electrophiles 
 
General Procedure A: Bromination of Secondary Alcohols.1 Triphenylphosphine (1.3 
equiv) and imidazole (1.3 equiv) were dissolved in dry CH2Cl2 (0.2 M), and the resulting 
solution was stirred at 0 °C under a nitrogen atmosphere.  Bromine (1.3 equiv) was added 
dropwise, and the reaction mixture was stirred at 0 °C for 5 min.  The alcohol was then added 
dropwise over 3 min.  The reaction mixture was allowed to warm to r.t., and then it was stirred 
for 6–12 h.  A saturated aqueous solution of NH4Cl was added to the reaction mixture, which 
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was then extracted two times with Et2O.  The combined organic layers were dried over MgSO4, 
filtered, and concentrated.  The residue was purified by flash chromatography (Et2O/hexane). 
General Procedure B: Bromination of Tertiary Alcohols.2 LiBr (2.0 equiv) was dissolved in 
48 wt% aqueous HBr, and the resulting solution was cooled to 0 °C.  The alcohol was added at 0 
°C, and the reaction mixture was allowed to warm to r.t. and stirred for 3 h.  The mixture was 
then diluted with Et2O and washed once with each of the following: deionized water, saturated 
aqueous NaHCO3 solution, and brine.  The organic layer was dried over Na2SO4, filtered, and 
concentrated.  The residue was purified by distillation under reduced pressure. 
 
The yields have not been optimized. 
 
O
CF3
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Br
  
1-((3-Bromopentyl)oxy)-2-(trifluoromethyl)benzene.  The bromide was prepared according 
to General Procedure A from the corresponding alcohol, 1-(2-(trifluoromethyl)phenoxy)pentan-
3-ol.  The product was purified by flash chromatography (0→2% Et2O/hexane).  Pale-yellow oil 
(1.42 g, 90%).  
1H NMR (500 MHz, CDCl3) δ 7.59 – 7.54 (m, 1H), 7.52 – 7.46 (m, 1H), 7.05 – 6.98 (m, 2H), 4.33 
– 4.19 (m, 3H), 2.37 (dddd, 1H, J = 15.0, 8.4, 5.8, 3.4 Hz), 2.23 (ddt, 1H, J = 14.7, 10.0, 4.5 Hz), 2.03 
– 1.87 (m, 2H), 1.10 (t, 3H, J = 7.3 Hz). 
13C NMR (126 MHz, CDCl3) δ 156.6, 133.3, 127.1 (q, J = 5.2 Hz), 123.7 (q, J = 272.3 Hz), 120.1, 
118.8 (q, J = 30.6 Hz), 112.8, 66.4, 55.9, 38.1, 32.4, 12.0. 
FT-IR (film) 2971, 1608, 1495, 1460, 1322, 1276, 1258, 1116, 1057, 1037, 754 cm-1. 
MS (EI) m/z (M+) calcd for C12H1479BrF3O: 310, found: 310. 
 
 
Cl
O Et
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1-((3-Bromopentyl)oxy)-4-chlorobenzene.  The bromide was prepared according to General 
Procedure A from the corresponding alcohol, 1-(4-chlorophenoxy)pentan-3-ol.  The product was 
purified by flash chromatography (0→2% Et2O/hexane).  Pale-yellow oil (1.01 g, 92%). 
1H NMR (500 MHz, CDCl3) δ 7.27 – 7.20 (m, 2H), 6.85 – 6.80 (m, 2H), 4.23 (ddt, 1H, J = 12.6, 
8.1, 2.8), 4.17 – 4.08 (m, 2H), 2.35 – 2.25 (m, 1H), 2.25 – 2.15 (m, 1H), 2.01 – 1.85 (m, 2H), 1.10 (t, 
3H, J = 7.3 Hz). 
13C NMR (126 MHz, CDCl3) δ 157.3, 129.3, 125.7, 115.8, 66.1, 55.9, 38.1, 32.4, 12.0. 
FT-IR (film) 2969, 2934, 2877, 1597, 1581, 1492, 1468, 1245, 823, 670 cm-1. 
MS (EI) m/z (M+) calcd for C11H1479BrClO: 276, found: 276. 
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3-Bromobutyl furan-2-carboxylate.  The bromide was prepared according to General 
Procedure A from the corresponding alcohol, 3-hydroxylbutyl furan-2-carboxylate.  The 
product was purified by flash chromatography (10% EtOAc/hexane).  Pale-yellow oil (1.34 g, 
54%). 
1H NMR (500 MHz, CDCl3) δ 7.57 (dd, 1H, J = 1.8, 0.9 Hz), 7.17 (dd, 1H, J = 3.5, 0.9 Hz), 6.51 
(dd, 1H, J = 3.5, 1.7 Hz), 4.53 – 4.47 (m, 1H), 4.42 (ddd, 1H, J = 11.2, 7.9, 5.7 Hz), 4.27 (dqd, 1H, J = 
9.0, 6.7, 4.5 Hz), 2.29 – 2.14 (m, 2H), 1.77 (d, 3H, J = 6.7 Hz). 
13C NMR (126 MHz, CDCl3) δ 158.5, 146.4, 144.4, 118.1, 111.8, 62.9, 46.7, 39.7, 26.5. 
FT-IR (film) 2969, 1724, 1473, 1296, 1179, 1116, 885, 761 cm-1. 
MS (EI) m/z (M+) calcd for C9H1179BrO3: 246, found: 246. 
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3-(3-Bromopentyl)-1-methyl-1H-indole.  The bromide was prepared according to General 
Procedure A from the corresponding alcohol, 1-(1-methyl-1H-indol-3-yl)pentan-3-ol.  The 
product was purified by flash chromatography (5→10% EtOAc/hexane).  Pale-yellow oil (0.86 g, 
34%). 
1H NMR (500 MHz, CDCl3) δ 7.63 (dt, 1H, J = 7.9, 1.0 Hz), 7.33 – 7.30 (m, 1H), 7.27 – 7.23 (m, 
1H), 7.15 – 7.10 (m, 1H), 6.91 (s, 1H), 4.03 (ddt, 1H, J = 8.6, 7.1, 5.2 Hz), 3.76 (s, 3H), 3.11 – 3.02 (m, 
1H), 2.98 – 2.89 (m, 1H), 2.27 – 2.12 (m, 2H), 1.95 – 1.85 (m, 2H), 1.06 (t, 3H, J = 7.2 Hz). 
13C NMR (126 MHz, CDCl3) δ 137.0, 127.7, 126.5, 121.5, 118.9, 118.6, 113.5, 109.2, 60.3, 39.3, 
32.6, 32.3, 23.2, 12.0. 
FT-IR (film) 2933, 1473, 1377, 1325, 1249, 802, 737 cm-1. 
MS (EI) m/z (M+) calcd for C14H1879BrN: 279, found: 281 (M++2). 
 
 
n-Pr Br
Me Me  
4-Bromo-4-methylheptane.  The bromide was prepared according to General Procedure B 
from the corresponding alcohol, 4-methylheptan-4-ol.  The product was distilled at 35 °C under 
reduced pressure (5 torr).  Colorless oil (3.01 g, 81%). 
1H NMR (500 MHz, CDCl3) δ 1.87 – 1.72 (m, 4H), 1.70 (s, 3H), 1.56 – 1.45 (m, 4H), 0.94 (t, 6H, J 
= 7.3 Hz). 
13C NMR (126 MHz, CDCl3) δ 74.1, 47.7, 31.5, 19.1, 14.1. 
FT-IR (film) 2960, 2873, 1465, 1380, 1142, 1125, 806, 745 cm-1. 
MS (EI) m/z (M+–Br) calcd for C8H17: 113, found: 113. 
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4-Bromo-4-butyltetrahydro-2H-pyran.  The bromide was prepared according to General 
Procedure B from the corresponding alcohol, 4-butyltetrahydro-2H-pyran-4-ol.  The product 
was distilled at 34 °C under reduced pressure (0.16 torr).  Colorless oil (3.43 g, 88%). 
1H NMR (500 MHz, CDCl3) δ 3.88 – 3.82 (m, 4H), 1.99 – 1.92 (m, 2H), 1.90 – 1.82 (m, 2H), 1.74 
(ddd, 2H, J = 14.7, 9.2, 7.7 Hz), 1.59 – 1.51 (m, 2H), 1.41 – 1.31 (m, 2H), 0.94 (t, 3H, J = 7.3 Hz). 
13C NMR (126 MHz, CDCl3) δ 72.6, 64.6, 46.8, 40.6, 26.6, 22.7, 14.0. 
FT-IR (film) 2956, 2862, 1467, 1241, 1140, 1106, 1017, 857, 813, 637 cm-1. 
MS (EI) m/z (M+–Br) calcd for C9H17O: 141, found: 141. 
 
 
III.  Nickel-Catalyzed Silylations of Unactivated Alkyl Halides 
 
General procedure for the preparation of solutions of ClZn–SiMe2Ph and ClZn–SiMePh2.3 
An oven-dried 40-mL vial equipped with a magnetic stir bar was charged with elemental 
lithium (174 mg, 25 mmol, 2.5 equiv), closed with a PTFE septum cap, and placed under 
vacuum.  The vial was refilled with argon, and this evacuation-refill cycle was repeated three 
times.  THF (10 mL) was then added via syringe, an argon-filled balloon was attached to the 
vial, and the suspension was cooled to 0 °C.  The chlorosilane (10 mmol, 1.0 equiv) was added 
via syringe, and then the reaction mixture was sonicated in an ice/water bath for 1 h, allowing 
the final bath temperature to reach ~10 °C.  The mixture was then stirred under argon at 0 °C for 
12 h.  Next, the vial was warmed to r.t., and the supernatant was removed from the residual 
lithium metal and transferred via syringe to an oven-dried, septum-capped 40-mL vial 
equipped with a stir bar under a nitrogen atmosphere; the silyllithium was titrated against 
diphenylacetic acid according to Kofron’s method.4 In air, ZnCl2 (dried with a heat gun under 
high vacuum for 20 min prior to the reaction; 1.0 equiv with respect to titrated silyllithium) was 
quickly weighed into an oven-dried 8-mL vial and placed under vacuum.  The vial was refilled 
with nitrogen, and this evacuation-refill cycle was repeated three times.  Dry THF was then 
added to form an ~1.2 M solution of ZnCl2.  This solution was added via syringe into a 40-mL 
vial equipped with a nitrogen-filled balloon that contained the silyllithium at 0 °C, and the 
reaction mixture was stirred at 0 °C for 30 min.  After warming to r.t., the mixture was filtered 
under a nitrogen atmosphere by injecting it through a syringe filter directly into a nitrogen-
filled, 20-mL scintillation vial sealed with a septum cap.  The silylzinc solution (routinely 
formed as an ~0.4 M solution) was titrated using Knochel’s method (at r.t.).5 
These solutions of silylzinc halide reagents can be stored for 1 month without deterioration 
under an inert atmosphere at −35 °C. 
Procedure for the preparation of a solution of ClZn–SiPh3.  An oven-dried 40-mL vial 
equipped with a magnetic stir bar was charged with elemental lithium (87 mg, 12.5 mmol, 2.5 
equiv) and chlorotriphenylsilane (1.47 g, 5.0 mmol, 1.0 equiv), closed with a PTFE septum cap, 
and placed under vacuum.  The vial was refilled with argon, and this evacuation-refill cycle was 
repeated three times.  THF (10 mL) was then added via syringe, an argon-filled balloon was 
attached to the vial, and the suspension was cooled to 0 °C and sonicated in an ice/water bath 
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for 2 h, allowing the final bath temperature to reach r.t. and forming a brownish-green slurry.  
The mixture was then stirred under argon at 0 °C for 12 h.  Next, the vial was warmed to r.t. and 
transferred into a nitrogen-filled glovebox.  The supernatant was removed from the residual 
lithium metal and filtered through a fritted funnel; the dark-green silyllithium was then titrated 
against diphenyl acetic acid.4 ZnCl2 (dried with a heat gun under high vacuum for 20 min prior 
to the reaction; 1.0 equiv with respect to titrated silyllithium) was weighed in the glovebox into 
an oven-dried 8-mL vial, and dry THF was added to form an ~1.2 M solution of ZnCl2.  Outside 
of the glovebox, this solution was added via syringe into a 40-mL vial that contained the 
silyllithium at 0 °C, and the reaction mixture was stirred at this temperature for 30 min.  After 
warming to r.t., the vial was transferred into the glovebox, and the reaction mixture was filtered 
by injecting it through a syringe filter.  The silylzinc solution was titrated using Knochel’s 
method for alkylzinc titration.5  
General procedure for nickel-catalyzed silylations of unactivated alkyl halides.  An oven-
dried 20-mL vial equipped with a magnetic stir bar was charged with NiBr2⋅diglyme (4.9 mg, 
0.014 mmol) and sealed with a PTFE septum cap.  The vial was placed under vacuum and 
refilled with nitrogen, and this evacuation-refill cycle was repeated three times.  DMA (2.1 mL) 
was added via syringe, and the mixture was stirred vigorously at r.t. for 10 min.  The alkyl 
bromide (0.7 mmol) was added via syringe, followed by stirring at r.t. for 5 min.  A nitrogen-
filled balloon was attached to the vial, which was then cooled to −20 °C.  The mixture was 
stirred for 5 min, and then the solution of the silylzinc in THF (1.05 mmol, 1.5 equiv) was added, 
the balloon was removed, the puncture hole was covered with vacuum grease, and the reaction 
mixture was stirred at −20 °C for 6–24 h.  The reaction was then quenched by the addition of 
ethanol (0.7 mL), followed by stirring for 1 min.  The mixture was next allowed to warm to r.t., 
and then it was diluted with Et2O (100 mL) and washed with deionized water (20 mL × 3).  The 
organic layer was dried over Na2SO4, filtered, and concentrated.  The residue was purified by 
flash chromatography. 
For electrophiles that are solids or are viscous liquids: The alkyl bromide (0.70 mmol) was 
weighed into an oven-dried 20-mL vial charged with a magnetic stir bar, which was then placed 
under vacuum.  The vial was refilled with nitrogen, and this evacuation-refill cycle was 
repeated three times.  The solution of NiBr2⋅diglyme in DMA prepared as described above was 
added to the alkyl bromide, and the mixture was stirred vigorously at r.t. for 5 min.  The 
procedure was then completed as described above. 
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(4-(4-Methoxyphenyl)butan-2-yl)dimethyl(phenyl)silane (Table 2, Entry 1).  The title 
compound was synthesized according to the General Procedure, using 2.0 mol% NiBr2⋅diglyme, 
from 1-(3-bromobutyl)-4-methoxybenzene (170 mg, 0.70 mmol).  Reaction time: 6 h.  The 
product was purified by column chromatography on silica gel (10→15% CH2Cl2/hexane).  
Colorless oil. 
First run: 167 mg (80% yield).  Second run: 164 mg (78% yield). 
This compound was also prepared on a 4.5 mmol scale, using (1-(3-bromobutyl)-4-
methoxybenzene (1.09 g, 4.50 mmol), the silylzinc reagent (0.46 M; 14.7 mL, 6.8 mmol, 1.5 
equiv), and NiBr2⋅diglyme (15.9 mg, 0.045 mmol; 1.0 mol%).  Reaction time: 12 h.  The title 
compound was isolated in 81% yield (1.09 g). 
1H NMR (500 MHz, CDCl3) δ 7.52 – 7.47 (m, 2H), 7.39 – 7.33 (m, 3H), 7.06 – 7.02 (m, 2H), 6.84 
– 6.80 (m, 2H), 3.80 (s, 3H), 2.72 (ddd, 1H, J = 14.4, 10.1, 4.8 Hz), 2.43 (ddd, 1H, J = 13.7, 9.7, 6.8 
Hz), 1.79 (dddd, 1H, J = 16.7, 9.7, 6.5, 3.2 Hz), 1.46 – 1.34 (m, 1H), 1.05 – 1.00 (m, 3H), 0.96 – 0.87 
(m, 1H), 0.26 (d, 6H, J = 4.6 Hz). 
13C NMR (126 MHz, CDCl3) δ 157.7, 138.6, 134.9, 133.9, 129.2, 128.8, 127.6, 113.7, 55.2, 33.91, 
33.89, 18.7, 14.0, −4.7, −5.0. 
FT-IR (film) 2952, 1512, 1246, 1112, 1038, 816, 701 cm-1. 
MS (EI) m/z (M+) calcd for C19H26OSi: 298, found: 298. 
 
 
SiMe2Ph
MeO
Me
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1-(4-Methoxyphenyl)-4-methylpentan-3-yl)dimethyl(phenyl)silane (Table 2, Entry 2).  The 
title compound was synthesized according to the General Procedure, using 5.0 mol% 
NiBr2⋅diglyme, from 1-(3-bromo-4-methylpentyl)-4-methoxybenzene (190 mg, 0.70 mmol).  
Reaction time: 24 h.  The product was purified by column chromatography on silica gel (0→20% 
CH2Cl2/hexane).  Colorless oil. 
First run: 175 mg (76% yield).  Second run: 173 mg (76% yield). 
1H NMR (500 MHz, CDCl3) δ 7.54 – 7.50 (m, 2H), 7.37 – 7.33 (m, 3H), 6.98 – 6.93 (m, 2H), 6.81  
– 6.77 (m, 2H), 3.79 (s, 3H), 2.53 – 2.36 (m, 2H), 1.99 (ddq, 1H, J = 10.7, 6.9, 3.5 Hz), 1.72 – 1.63 (m, 
2H), 0.96 (d, 3H, J = 6.8 Hz), 0.92 – 0.87 (m, 4H), 0.34 (d, 6H, J = 3.7 Hz). 
13C NMR (126 MHz, CDCl3) δ 157.6, 140.1, 135.0, 133.8, 129.2, 128.6, 127.6, 113.6, 55.2, 35.8, 
32.6, 29.3, 28.6, 22.9, 21.3, −1.9, −2.7. 
FT-IR (film) 2953, 1511, 1246, 1110, 1039, 820, 701 cm-1. 
MS (EI) m/z (M+) calcd for C21H30OSi: 326, found: 326. 
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(1-(4-Methoxyphenyl)-4,4-dimethylpentan-3-yl)dimethyl(phenyl)silane (Table 2, Entry 3).  
The title compound was synthesized according to the General Procedure, using 5.0 mol% 
NiBr2⋅diglyme, from 1-(3-bromo-4,4-dimethylpentyl)-4-methoxybenzene (200 mg, 0.70 mmol).  
Reaction time: 24 h.  The product was purified by column chromatography on silica gel (0→20% 
CH2Cl2/hexane).  Colorless oil. 
First run: 161 mg (68% yield).  Second run: 161 mg (68% yield). 
1H NMR (500 MHz, CDCl3) δ 7.62 – 7.55 (m, 2H), 7.41 – 7.35 (m, 3H), 6.87 – 6.81 (m, 2H), 6.80 
– 6.75 (m, 2H), 3.78 (s, 3H), 2.38 (ddd, 1H, J = 13.2, 11.5, 5.9 Hz), 2.09 (ddd, 1H, J = 13.2, 11.7, 5.6 
Hz), 1.67 – 1.52 (m, 2H), 0.96 (s, 9H), 0.75 (dd, 1H, J = 4.9, 3.8 Hz), 0.43 (s, 3H), 0.38 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 157.6, 141.0, 135.2, 134.0, 129.1, 128.5, 127.6, 113.6, 55.2, 38.76, 
38.74, 34.8, 30.9, 30.6, 0.1, −2.0. 
FT-IR (film) 2953, 1512, 1246, 816, 702 cm-1. 
MS (EI) m/z (M+) calcd for C22H32OSi: 340, found: 325 (M+−CH3). 
 
 
O
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Dimethyl(phenyl)(1-(2-(trifluoromethyl)phenoxy)pentan-3-yl)silane (Table 2, Entry 4).  
The title compound was synthesized according to the General Procedure, using 2.0 mol% 
NiBr2⋅diglyme, from 1-((3-bromopentyl)oxy)-2-(trifluoromethyl)benzene (218 mg, 0.70 mmol).  
Reaction time: 6 h.  The product was purified by column chromatography on silica gel (hexane).  
Colorless oil. 
First run: 145 mg (57% yield).  Second run: 166 mg (65% yield). 
1H NMR (500 MHz, CDCl3) δ 7.58 – 7.52 (m, 3H), 7.43 – 7.39 (m, 1H), 7.37 – 7.33 (m, 3H), 6.99 
– 6.94 (m, 1H), 6.79 (d, 1H, J = 8.4 Hz), 3.97 – 3.92 (m, 2H), 1.99 (dtd, 1H, J = 14.3, 7.2, 5.1 Hz), 1.80 
(ddt, 1H, J = 14.4, 8.3, 6.1 Hz), 1.61 (dqd, 1H, J = 14.0, 7.4, 5.1 Hz), 1.46 – 1.37 (m, 1H), 1.10 (ddt, 
1H, J = 8.3, 7.1, 5.1 Hz), 0.93 (t, 3H, J = 7.4 Hz), 0.33 (d, 6H, J = 3.7 Hz). 
13C NMR (126 MHz, CDCl3) δ 156.9 (d, J = 1.8 Hz), 138.8, 133.8, 133.1, 128.8, 127.7, 127.0 (q, J = 
5.3 Hz), 127.8 (q, J = 272.3 Hz), 119.6, 118.7 (q, J = 30.5 Hz), 112.6, 67.9, 28.6, 22.9, 22.5, 13.8, −3.7, 
−4.2. 
FT-IR (film) 2959, 1610, 1460, 1323, 1275, 1258, 1133, 1117, 1057, 1038, 830, 810, 755, 701 cm-1. 
MS (EI) m/z (M+) calcd for C20H25F3OSi: 366, found: 351 (M+−CH3). 
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tert-Butyl 4-(dimethyl(phenyl)silyl)piperidine-1-carboxylate (Table 2, Entry 5).  The title 
compound was synthesized according to the General Procedure, using 2.0 mol% NiBr2⋅diglyme, 
from tert-butyl 4-bromopiperidine-1-carboxylate (185 mg, 0.70 mmol).  Reaction time: 6 h.  The 
product was purified by column chromatography on silica gel (8:4:1 hexane/CH2Cl2/Et2O).  
Colorless oil. 
First run: 168 mg (75% yield).  Second run: 162 mg (73% yield). 
1H NMR (500 MHz, CDCl3) δ 7.50 – 7.45 (m, 2H), 7.38 – 7.33 (m, 3H), 4.20 – 4.00 (br, 2H), 2.64 
– 2.54 (m, 2H), 1.61 – 1.52 (m, 2H), 1.44 (s, 9H), 1.36 – 1.21 (m, 2H), 0.95 – 0.84 (m, 1H), 0.26 (s, 
6H). 
13C NMR (126 MHz, CDCl3) δ 154.9, 137.5, 133.9, 129.0, 127.8, 79.1, 45.7, 28.5, 26.6, 23.9, −5.4. 
FT-IR (film) 2928, 1693, 1427, 1248, 1167, 832, 809 cm-1. 
MS (EI) m/z (M+) calcd for C18H29NO2Si: 319, found: 218 (M+−Boc). 
 
 
NPh
Me
Me
SiMe2Ph
 
N-(3-(Dimethyl(phenyl)silyl)butyl)-N-methylaniline (Table 2, Entry 6).  The title 
compound was synthesized according to the General Procedure, using 2.0 mol% NiBr2⋅diglyme, 
from N-(3-bromobutyl)-N-methylaniline (170 mg, 0.70 mmol).  Reaction time: 6 h.  The product 
was purified by column chromatography on silica gel (10→20% CH2Cl2/hexane).  Pale-yellow 
oil. 
First run: 158 mg (76% yield).  Second run: 160 mg (77% yield). 
1H NMR (500 MHz, CDCl3) δ 7.54 – 7.49 (m, 2H), 7.40 – 7.33 (m, 3H), 7.23 – 7.17 (m, 2H), 6.70 
– 6.60 (m, 3H), 3.41 (ddd, 1H, J = 14.9, 10.6, 4.6 Hz), 3.19 (ddd, 1H, J = 14.5, 10.3, 6.0 Hz), 2.86 (s, 
3H), 1.81 (dddd, 1H, J = 13.8, 10.6, 6.1, 3.4 Hz), 1.37 – 1.26 (m, 1H), 1.06 (d, 3H, J = 7.3 Hz), 0.93 – 
0.85 (m, 1H), 0.28 (d, 6H, J = 2.9 Hz). 
13C NMR (126 MHz, CDCl3) δ 149.4, 138.3, 133.9, 129.1, 128.9, 127.7, 115.9, 112.1, 52.2, 37.9, 
28.4, 17.1, 14.4, −4.7, −5.1. 
FT-IR (film) 2953, 1600, 1506, 1248, 1112, 833, 814, 746, 701, 691 cm-1. 
MS (EI) m/z (M+) calcd for C19H27NSi: 297, found: 297. 
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N-Butyl-N-(3-(dimethyl(phenyl)silyl)butyl)methanesulfonamide (Table 2, Entry 7).  The 
title compound was synthesized according to the General Procedure, using 2.0 mol% 
NiBr2⋅diglyme, from N-(3-bromobutyl)-N-butylmethanesulfonamide (200 mg, 0.70 mmol).  
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Reaction time: 6 h.  The product was purified by column chromatography on silica gel (25→35% 
Et2O/hexane).  Colorless oil. 
First run: 192 mg (80% yield).  Second run: 182 mg (76% yield). 
1H NMR (500 MHz, CDCl3) δ 7.52 – 7.47 (m, 2H), 7.38 – 7.33 (m, 3H), 3.18 (ddd, 1H, J = 14.3, 
9.9, 4.6 Hz), 3.13 – 2.96 (m, 3H), 2.74 (s, 3H), 1.75 (dddd, 1H, J = 13.4, 10.1, 6.8, 3.5 Hz), 1.52 – 1.40 
(m, 2H), 1.33 – 1.20 (m, 3H), 0.99 (d, 3H, J = 7.3 Hz), 0.91 – 0.85 (m, 4H), 0.28 (d, 6H, J = 0.7 Hz). 
13C NMR (126 MHz, CDCl3) δ 138.0, 133.9, 129.0, 127.8, 47.4, 47.0, 38.3, 30.8, 30.7, 19.9, 16.8, 
14.0, 13.6, −4.7, −5.4. 
FT-IR (film) 2956, 2869, 1334, 1249, 1146, 1112, 835, 816, 773, 702 cm-1. 
MS (EI) m/z (M+) calcd for C17H31NO2SSi: 341, found: 326 (M+−CH3). 
 
 
Cl
O Et
SiMe2Ph
 
(1-(4-Chlorophenoxy)pentan-3-yl)dimethyl(phenyl)silane (Table 2, Entry 8).  The title 
compound was synthesized according to the General Procedure, using 2.0 mol% NiBr2⋅diglyme, 
from 1-((3-bromopentyl)oxy)-4-chlorobenzene (195 mg, 0.70 mmol).  Reaction time: 6 h.  The 
product was purified by column chromatography on silica gel (0→2% Et2O/hexane).  Colorless 
oil. 
First run: 146 mg (63% yield).  Second run: 156 mg (67% yield). 
1H NMR (500 MHz, CDCl3) δ 7.55 – 7.50 (m, 2H), 7.39 – 7.32 (m, 3H), 7.21 – 7.16 (m, 2H), 6.73 
– 6.67 (m, 2H), 3.88 – 3.75 (m, 2H), 1.93 (dddd, 1H, J = 13.6, 8.2, 6.6, 5.1 Hz), 1.77 (dtd, 1H, J = 
13.8, 8.0, 5.7 Hz), 1.61 (dqd, 1H, J = 13.9, 7.5, 5.0 Hz), 1.44 – 1.36 (m, 1H), 1.00 – 0.90 (m, 4H), 0.32 
(d, 6H, J = 4.1 Hz). 
13C NMR (126 MHz, CDCl3) δ 157.6, 138.8, 133.8, 129.2, 128.9, 127.8, 125.3, 115.7, 67.9, 28.7, 
23.7, 22.7, 13.9, −3.7, −4.2. 
FT-IR (film) 2957, 1492, 1244, 823, 701 cm-1. 
MS (EI) m/z (M+) calcd for C19H25ClOSi: 332, found: 332. 
 
 
O
O Me
O SiMe2Ph
 
3-(Dimethyl(phenyl)silyl)butyl furan-2-carboxylate (Table 2, Entry 9).  The title compound 
was synthesized according to the General Procedure, using 2.0 mol% NiBr2⋅diglyme, from 3-
bromobutyl furan-2-carboxylate (173 mg, 0.70 mmol).  Reaction time: 6 h.  The product was 
purified by column chromatography on silica gel (10→15% CH2Cl2/hexane).  Colorless oil. 
First run: 158 mg (75% yield).  Second run: 158 mg (75% yield). 
1H NMR (500 MHz, CDCl3) δ 7.58 – 7.56 (m, 1H), 7.53 – 7.48 (m, 2H), 7.38 – 7.33 (m, 3H), 7.14 
(dd, 1H, J = 3.5, 0.9 Hz), 6.50 (dd, 1H, J = 3.5, 1.7 Hz), 4.40 – 4.22 (m, 2H), 2.01 – 1.91 (m, 1H), 1.54 
– 1.41 (m, 1H), 1.09 – 1.00 (m, 4H), 0.29 (d, 6H, J = 4.2 Hz). 
13C NMR (126 MHz, CDCl3) δ 158.7, 146.1, 145.0, 137.9, 133.9, 129.0, 127.7, 117.6, 111.7, 64.3, 
30.6, 15.9, 13.9, −4.9, −5.2. 
 S–10 
FT-IR (film) 2956, 1728, 1475, 1295, 1180, 1117, 833, 815, 764, 702 cm-1. 
MS (EI) m/z (M+) calcd for C17H22O3Si: 302, found: 302. 
 
 
N
Me
Et
SiMe2Ph
 
3-(3-(Dimethyl(phenyl)silyl)pentyl)-1-methyl-1H-indole (Table 2, Entry 10).  The title 
compound was synthesized according to the General Procedure, using 5.0 mol% NiBr2⋅diglyme, 
from 3-(3-bromopentyl)-1-methyl-1H-indole (196 mg, 0.70 mmol).  Reaction time: 6 h.  The 
product was purified by column chromatography on silica gel (10→15% CH2Cl2/hexane).  Pale-
yellow oil. 
First run: 186 mg (79% yield).  Second run: 185 mg (79% yield). 
1H NMR (500 MHz, CDCl3) δ 7.57 – 7.53 (m, 2H), 7.47 (dt, 1H, J = 7.9, 0.9 Hz), 7.40 – 7.34 (m, 
3H), 7.30 – 7.27 (m, 1H), 7.24 – 7.20 (m, 1H), 7.10 – 7.07 (m, 1H), 6.72 (s, 1H), 3.73 (s, 3H), 2.79 
(dddd, 1H, J = 14.6, 10.8, 5.1, 0.9 Hz), 2.65 (dddd, 1H, J = 14.5, 10.9, 6.0, 0.9 Hz), 1.89 (dddd, 1H, J 
= 13.7, 10.7, 6.0, 4.7 Hz), 1.79 – 1.62 (m, 2H), 1.56 – 1.45 (m, 1H), 1.01 – 0.90 (m, 4H), 0.33 (d, 6H, J 
= 3.3 Hz). 
13C NMR (126 MHz, CDCl3) δ 139.5, 137.1, 133.9, 128.7, 128.0, 127.7, 125.8, 121.3, 119.1, 118.4, 
115.7, 109.0, 32.5, 30.2, 27.1, 24.8, 22.4, 13.8, −3.5, −3.7. 
FT-IR (film) 2955, 2929, 1484, 1472, 1426, 1376, 1325, 1247, 1111, 830, 810, 736, 701 cm-1. 
MS (EI) m/z (M+) calcd for C22H29NSi: 335, found: 335. 
 
 
Me
SiMe2PhMe
MeO  
(4-(4-Methoxyphenyl)-2-methylbutan-2-yl)dimethyl(phenyl)silane (Table 3, Entry 1).  The 
title compound was synthesized according to the General Procedure, using 10 mol% 
NiBr2⋅diglyme, from 1-(3-bromo-3-methylbutyl)-4-methoxybenzene (180 mg, 0.70 mmol).  
Reaction time: 24 h.  The product was purified by column chromatography on silica gel 
(10→20% CH2Cl2/hexane).  Colorless oil. 
First run: 154 mg (70% yield).  Second run: 150 mg (69% yield).  The isolated product 
includes a small amount of a non-polar impurity that co-elutes with the desired product during 
column chromatography. 
1H NMR (500 MHz, CDCl3) δ 7.56 – 7.50 (m, 2H), 7.42 – 7.33 (m, 3H), 7.07 – 7.01 (m, 2H), 6.87 
– 6.78 (m, 2H), 3.79 (s, 3H), 2.51 – 2.44 (m, 2H), 1.58 – 1.50 (m, 2H), 0.99 (s, 6H), 0.32 (s, 6H). 
13C NMR (126 MHz, CDCl3) δ 157.5, 137.8, 135.6, 134.5, 129.1, 128.8, 127.5, 113.7, 55.2, 41.6, 
29.2, 23.1, 20.1, −5.6. 
FT-IR (film) 2953, 1512, 1246, 1039, 817, 770, 736, 701 cm-1. 
MS (EI) m/z (M+) calcd for C20H28OSi: 312, found: 312. 
 
 S–11 
 
n-Pr SiMe2Ph
Me Me  
Dimethyl(4-methylheptan-4-yl)(phenyl)silane (Table 3, Entry 2).  The title compound was 
synthesized according to the General Procedure, using 10 mol% NiBr2⋅diglyme, from 4-bromo-
4-methylheptane (135 mg, 0.70 mmol).  Reaction time: 24 h.  The product was purified by 
column chromatography on silica gel (hexane). Colorless oil. 
First run: 94 mg (54% yield).  Second run: 92 mg (53% yield). 
1H NMR (500 MHz, CDCl3) δ 7.56 – 7.49 (m, 2H), 7.37 – 7.31 (m, 3H), 1.36 – 1.17 (m, 8H), 0.91 
– 0.80 (m, 9H), 0.30 (s, 6H). 
13C NMR (126 MHz, CDCl3) δ 139.0, 134.5, 128.5, 127.4, 39.3, 24.0, 22.2, 17.5, 15.2, –4.1. 
FT-IR (film) 2956, 2871, 1467, 1427, 1248, 1112, 816, 767, 735, 700 cm-1. 
MS (EI) m/z (M+) calcd for C16H28Si: 248, found: 248. 
 
 
Me Me
SiMe2PhMe
Me
 
(3,7-Dimethyloct-6-en-3-yl)dimethyl(phenyl)silane (Table 3, Entry 3).  The title compound 
was synthesized according to the General Procedure, using 10 mol% NiBr2⋅diglyme, from 6-
bromo-2,6-dimethyloct-2-ene (153 mg, 0.70 mmol).  Reaction time: 24 h.  The product was 
purified by column chromatography on silica gel (hexane).  Colorless oil. 
First run: 92 mg (48% yield).  Second run: 95 mg (49% yield). 
1H NMR (500 MHz, CDCl3) δ 7.56 – 7.49 (m, 2H), 7.38 – 7.30 (m, 3H), 5.08 – 5.03 (m, 1H), 1.92 
– 1.84 (m, 2H), 1.71 – 1.65 (m, 3H), 1.58 – 1.56 (m, 3H), 1.41 – 1.24 (m, 4H), 0.89 (s, 3H), 0.81 (t, 
3H, J = 7.5 Hz), 0.32 (s, 6H). 
13C NMR (126 MHz, CDCl3) δ 138.9, 134.5, 130.8, 128.6, 127.4, 125.4, 36.0, 28.6, 25.7, 23.8, 23.0, 
21.6, 17.6, 8.7, −4.1, −4.2. 
FT-IR (film) 2960, 1460, 1427, 1377, 1248, 1110, 830, 811, 767, 735, 701 cm-1. 
MS (EI) m/z (M+) calcd for C18H30Si: 274, found: 274. 
 
 
n-Pentyl
SiMe2Ph
 
Dimethyl(1-pentylcyclobutyl)(phenyl)silane (Table 3, Entry 4).  The title compound was 
synthesized according to the General Procedure, using 10 mol% NiBr2⋅diglyme, from 1-bromo-
1-pentylcyclobutane (144 mg, 0.70 mmol).  Reaction time: 24 h.  The product was purified by 
column chromatography on silica gel (hexane).  Colorless oil. 
First run: 121 mg (66% yield).  Second run: 132 mg (73% yield). 
1H NMR (500 MHz, CDCl3) δ 7.58 – 7.53 (m, 2H), 7.39 – 7.32 (m, 3H), 2.13 – 2.05 (m, 2H), 1.93 
– 1.76 (m, 3H), 1.70 – 1.59 (m, 1H), 1.51 – 1.42 (m, 2H), 1.31 – 1.15 (m, 6H), 0.86 (t, 3H, J = 7.1 Hz), 
0.33 (s, 6H). 
 S–12 
13C NMR (126 MHz, CDCl3) δ 138.9, 134.1, 128.7, 127.5, 39.6, 32.9, 29.2, 28.3, 25.2, 22.6, 17.2, 
14.1, −4.9. 
FT-IR (film) 2924, 2853, 1247, 1112, 815, 699 cm-1. 
MS (EI) m/z (M+) calcd for C17H28Si: 260, found: 260. 
 
 
SiMe2Ph
Me  
Dimethyl(1-methylcyclohexyl)(phenyl)silane (Table 3, Entry 5).  The title compound was 
synthesized according to the General Procedure, using 10 mol% NiBr2⋅diglyme, from 1-bromo-
1-methylcyclohexane (124 mg, 0.70 mmol).  Reaction time: 24 h.  The product was purified by 
column chromatography on silica gel (hexane).  Colorless oil. 
First run: 113 mg (69% yield).  Second run: 118 mg (72% yield).  The isolated product 
includes a small amount of a non-polar impurity that co-elutes with the desired product during 
column chromatography. 
1H NMR (500 MHz, CDCl3) δ 7.54 – 7.48 (m, 2H), 7.38 – 7.32 (m, 3H), 1.65 – 1.56 (m, 1H), 1.55 
– 1.40 (m, 4H), 1.40 – 1.26 (m, 4H), 1.17 – 1.05 (m, 1H), 0.95 (s, 3H), 0.27 (s, 6H). 
13C NMR (126 MHz, CDCl3) δ 137.7, 134.7, 128.6, 127.3, 31.9, 26.7, 20.3, 20.0, 17.9, −6.5. 
FT-IR (film) 2916, 1426, 1246, 1106, 815, 766, 734, 699 cm-1. 
MS (EI) m/z (M+) calcd for C15H24Si: 232, found: 232. 
 
 
O SiMe2Phn-Bu  
(4-Butyltetrahydro-2H-pyran-4-yl)dimethyl(phenyl)silane (Table 3, Entry 6).  The title 
compound was synthesized according to the General Procedure, using 2.0 mol% NiBr2⋅diglyme, 
from 4-bromo-4-butyltetrahydro-2H-pyran (155 mg, 0.70 mmol).  Reaction time: 24 h.  The 
product was purified by column chromatography on silica gel (5→10% Et2O/hexane).  Colorless 
oil. 
First run: 145 mg (75% yield).  Second run: 142 mg (73% yield). 
1H NMR (500 MHz, CDCl3) δ 7.52 – 7.47 (m, 2H), 7.38 – 7.32 (m, 3H), 3.71 – 3.56 (m, 4H), 1.90 
– 1.79 (m, 2H), 1.61 – 1.54 (m, 2H), 1.37 – 1.30 (m, 2H), 1.28 – 1.20 (m, 2H), 1.17 – 1.09 (m, 2H), 
0.85 (t, 3H, J = 7.3 Hz), 0.32 (s, 6H). 
13C NMR (126 MHz, CDCl3) δ 137.9, 134.5, 128.9, 127.6, 62.6, 31.5, 30.6, 27.6, 23.8, 21.8, 14.0, 
−4.7. 
FT-IR (film) 2953, 2931, 2858, 1427, 1249, 1105, 866, 826, 809, 767, 736, 701 cm-1. 
MS (EI) m/z (M+) calcd for C17H28OSi: 276, found: 261 (M+−CH3). 
 
 
 S–13 
Me
SiMe2Ph
MeO  
(4-(4-Methoxyphenyl)butan-2-yl)dimethyl(phenyl)silane (eq 3).  The title compound was 
synthesized according to the General Procedure, using 2.0 mol% NiBr2⋅diglyme, from 1-(3-
iodobutyl)-4-methoxybenzene (203 mg, 0.70 mmol).  Reaction time: 6 h.  The product was 
purified by column chromatography on silica gel (10→25% CH2Cl2/hexane).  Colorless oil. 
First run: 130 mg (62% yield).  Second run: 130 mg (62% yield). 
For the characterization data, see Table 2, Entry 1 (above). 
 
 
SiMe2Ph  
(Adamantan-1-yl)dimethyl(phenyl)silane (eq 4).  The title compound was synthesized 
according to the General Procedure, using 10 mol% NiBr2⋅diglyme, from 1-iodoadamantane (183 
mg, 0.70 mmol).  Reaction time: 24 h.  The product was purified by column chromatography on 
silica gel (hexane).  Colorless oil. 
First run: 102 mg (54% yield).  Second run: 105 mg (56% yield). 
1H NMR (500 MHz, CDCl3) δ 7.51 – 7.46 (m, 2H), 7.39 – 7.33 (m, 3H), 1.84 – 1.81 (m, 3H), 1.77 
– 1.63 (m, 12H), 0.23 (s, 6H). 
13C NMR (126 MHz, CDCl3) δ 137.2, 134.6, 128.6, 127.3, 37.5, 37.1, 27.6, 21.5, −7.3. 
FT-IR (film) 2896, 2843, 1426, 1252, 1115, 852, 827, 799, 764, 733, 699 cm-1. 
MS (ESI) m/z (M+) calcd for C18H26Si: 270, found: 270. 
The spectral data are in agreement with literature data.6 
 
 
SiMePh2
Me
MeO  
(4-(4-Methoxyphenyl)butan-2-yl)(methyl)diphenylsilane (eq 5).  The title compound was 
synthesized according to the General Procedure, using 10 mol% NiBr2⋅diglyme, from 1-(3-
bromobutyl)-4-methoxybenzene (170 mg, 0.70 mmol) and a silylzinc reagent prepared from 
chloro(methyl)diphenylsilane.  Reaction time: 24 h.  The product was purified by column 
chromatography on silica gel (10→20% CH2Cl2/hexane).  Colorless oil. 
First run: 224 mg (89% yield).  Second run: 216 mg (85% yield). 
1H NMR (500 MHz, CDCl3) δ 7.52 – 7.48 (m, 4H), 7.41 – 7.32 (m, 6H), 7.05 – 7.00 (m, 2H), 6.85 
– 6.80 (m, 2H), 3.81 (s, 3H), 2.76 (ddd, 1H, J = 14.0, 9.6, 4.7 Hz), 2.47 (ddd, 1H, J = 13.7, 9.2, 7.4 
Hz), 1.94 – 1.84 (m, 1H), 1.46 (dddd, 1H, J = 13.6, 10.8, 9.2, 4.7 Hz), 1.39 – 1.30 (m, 1H), 1.10 (d, 
3H, J = 7.3 Hz), 0.54 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ 157.6, 136.5, 136.3, 134.81, 134.78, 134.6, 129.4, 129.03, 128.99, 
127.71, 127.69, 113.6, 55.2, 33.77, 33.71, 16.8, 14.0, −6.4. 
 S–14 
FT-IR (film) 3068, 2952, 2852, 1611, 1511, 1427, 1244, 1110, 1037, 785, 699 cm-1. 
MS (EI) m/z (M+) calcd for C24H28OSi: 360, found: 360. 
 
 
SiPh3
Me
MeO  
(4-(4-Methoxyphenyl)butan-2-yl)triphenylsilane (eq 5).  The title compound was 
synthesized according to the General Procedure, using 10 mol% NiBr2⋅diglyme, from 1-(3-
bromobutyl)-4-methoxybenzene (170 mg, 0.70 mmol) and a silylzinc reagent prepared from 
chlorotriphenylsilane.  Reaction time: 24 h; reaction temperature: r.t.  The product was purified 
by column chromatography on silica gel (10→20% CH2Cl2/hexane).  Colorless, viscous oil. 
First run: 234 mg (79% yield).  Second run: 236 mg (80% yield). 
1H NMR (500 MHz, CDCl3) δ 7.56 – 7.53 (m, 6H), 7.44 – 7.40 (m, 3H), 7.39 – 7.34 (m, 6H), 7.09 
– 7.05 (m, 2H), 6.88 – 6.84 (m, 2H), 3.82 (s, 3H), 2.83 (ddd, 1H, J = 13.6, 9.0, 4.6 Hz), 2.56 (dt, 1H, J 
= 13.6, 8.3 Hz), 2.10 (dddd, 1H, J = 13.7, 9.0, 8.0, 2.3 Hz), 1.75 – 1.66 (m, 1H), 1.58 – 1.48 (m, 1H), 
1.25 (d, 3H, J = 7.3 Hz). 
13C NMR (126 MHz, CDCl3) δ 157.6, 136.0, 134.5, 134.3, 129.5, 129.2, 127.7, 113.6, 55.2, 34.0, 
33.6, 15.8, 14.3. 
FT-IR (film) 3067, 2931, 1511, 1428, 1246, 1109, 741, 700 cm-1. 
MS (ESI) m/z (M+) calcd for C29H30OSi: 422, found: 345 (M+−C6H5). 
 
 
SiMe2Ph  
(exo-Bicyclo[2.2.1]heptan-2-yl)dimethyl(phenyl)silane (eq 6) [65118-96-9].  The title 
compound was synthesized according to the General Procedure, using 5.0 mol% NiBr2⋅diglyme, 
from exo-2-bromobicyclo[2.2.1]heptane (123 mg, 0.70 mmol).  Reaction time: 24 h.  The product 
was purified by column chromatography on silica gel (hexane).  Colorless oil.  The 
diastereoselectivity was determined by GC analysis of the unpurified cross-coupling product. 
The major diastereomer was determined to be the exo isomer by comparing the 1H NMR 
data with the data reported in the literature.7 Additionally, after converting the product mixture 
to the corresponding bicyclo[2.2.1]heptan-2-ol via a Fleming oxidation,8 the major alcohol 
product was confirmed to be the exo isomer by comparing with commercially available exo-
bicyclo[2.2.1]heptan-2-ol. 
First run: 136 mg (84% yield, exo/endo = 7:1).  Second run: 137 mg (85% yield, exo/endo = 
7:1). 
1H NMR (500 MHz, CDCl3) δ (major, exo) 7.57 – 7.52 (m, 2H), 7.38 – 7.35 (m, 3H), 2.25 – 2.23 
(m, 2H), 1.56 – 1.39 (m, 4H), 1.29 – 1.20 (m, 2H), 1.08 (m, 2H), 0.86 – 0.82 (m, 1H), 0.27 (s, 3H), 
0.25 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ (major, exo) 139.4, 133.9, 128.7, 127.6, 37.9, 37.8, 36.9, 34.3, 32.7, 
28.9, 28.5, –4.06, –4.10. 
 S–15 
FT-IR (film) 2947, 2865, 1427, 1246, 1113, 698 cm-1. 
MS (ESI) m/z (M+) calcd for C15H22Si: 230, found: 230. 
 
 
SiMe2Ph  
(exo-Bicyclo[2.2.1]heptan-2-yl)dimethyl(phenyl)silane (eq 7) [65118-96-9].  The title 
compound was synthesized according to the General Procedure, using 5.0 mol% catalyst 
loading, from endo-2-bromobicyclo[2.2.1]heptane (123 mg, 0.70 mmol).  Reaction time: 24 h.  The 
product was purified by column chromatography on silica gel (hexane).  Colorless oil.  The 
diastereoselectivity was determined by GC analysis of the unpurified cross-coupling product. 
First run: 121 mg (75% yield, exo/endo = 7:1).  Second run: 114 mg (71% yield, exo/endo = 
7:1). 
1H NMR (500 MHz, CDCl3) δ (major, exo) 7.56 – 7.52 (m, 2H), 7.38 – 7.35 (m, 3H), 2.25 – 2.23 
(m, 2H), 1.57 – 1.39 (m, 4H), 1.29 – 1.20 (m, 2H), 1.08 (m, 2H), 0.86 – 0.81 (m, 1H), 0.27 (s, 3H), 
0.25 (s, 3H). 
13C NMR (126 MHz, CDCl3) δ (major, exo) 139.3, 133.9, 128.7, 127.6, 37.9, 37.8, 36.9, 34.3, 32.7, 
28.9, 28.5, –4.06, –4.10. 
FT-IR (film) 2946, 2864, 1426, 1246, 1113, 698 cm-1. 
MS (ESI) m/z (M+) calcd for C15H22Si: 230, found: 230. 
 
Competition Experiments (eqs 8 and 9).  In a nitrogen-filled glovebox, NiBr2⋅diglyme (3.5 
mg, 0.010 mmol) was added to an oven-dried 4-mL vial equipped with a stir bar.  DMA (0.3 mL) 
was added to the vial, and then the vial was closed with a PTFE septum cap and removed from 
the glovebox.  The mixture was vigorously stirred at r.t. for 10 min, and then the two alkyl 
bromides (0.10 mmol each) were added to the vial via syringe, and the mixture was stirred at r.t. 
for 5 min.  Next, the vial was cooled to –20 °C, and the reaction mixture was stirred for 5 min.  
Then, a solution of the silylzinc reagent (0.060 M; 0.33 mL, 0.020 mmol, 0.20 equiv) was added in 
one portion.  The reaction mixture was stirred at −20 °C for 4 h, and then the reaction was 
quenched with ethanol (0.1 mL).  n-Tetradecane (26 µL) was added to the vial as an internal 
standard, and the reaction mixture was analyzed via GC. 
 
 
Effect of TEMPO.  
 
Entry 1 (no TEMPO): In a nitrogen-filled glovebox, NiBr2⋅diglyme (7.0 mg, 0.020 mmol) was 
added to an oven-dried 4-mL vial equipped with a stir bar.  DMA (3.0 mL) was added to the 
vial, and then the vial was closed with a PTFE septum cap.  The mixture was vigorously stirred 
at r.t. for 10 min.  Then, the stock solution of the catalyst (0.30 mL; 0.0020 mmol) was added to a 
4-mL vial that contained the alkyl bromide (0.10 mmol) and a stir bar.  The vial was closed with 
a PTFE septum cap and removed from the glovebox.  The reaction mixture was stirred at r.t. for 
5 min, and then the vial was cooled to –20 °C and the reaction mixture was stirred for an 
additional 5 min.  A nitrogen-filled balloon was affixed to the vial.  Next, a solution of the 
silylzinc reagent in THF (0.15 mmol, 1.5 equiv) was added, and the balloon was removed.  The 
 S–16 
reaction mixture was stirred at –20 °C for 2 h, and then the reaction was quenched by the 
addition of ethanol (0.1 mL).  The mixture was allowed to warm to r.t., n-tetradecane (26 µL) 
was added to the vial, and the reaction mixture was analyzed by GC. 
 
Entries 2 and 3 (with TEMPO): In a nitrogen-filled glovebox, NiBr2⋅diglyme (7.0 mg, 0.020 
mmol) was added to an oven-dried 4-mL vial equipped with a stir bar.  DMA (3.0 mL) was 
added to the vial, and then the vial was closed with a PTFE septum cap.  The mixture was 
vigorously stirred at r.t. for 10 min.  Then, the stock solution of the catalyst (0.30 mL; 0.0020 
mmol) was added to a 4-mL vial that contained the alkyl bromide (0.10 mmol), TEMPO (1.6 mg, 
0.010 mmol; or, 16 mg, 0.10 mmol), and a stir bar.  The vial was closed with a PTFE septum cap 
and removed from the glovebox.  The reaction mixture was stirred at r.t. for 5 min, and then the 
vial was cooled to –20 °C and the reaction mixture was stirred for an additional 5 min.  A 
nitrogen-filled balloon was affixed to the vial.  Next, a solution of the silylzinc reagent in THF 
(0.15 mmol, 1.5 equiv) was added, and the balloon was removed.  The reaction mixture was 
stirred at –20 °C for 2 h, and then the reaction was quenched by the addition of ethanol (0.1 mL).  
The mixture was allowed to warm to r.t., n-tetradecane (26 µL) was added to the vial, and the 
reaction mixture was analyzed by GC. 
 
Table S1.  Effect of TEMPO. 
1.5 equiv
0
10
100
86
24
<2
1
2
3
entry X mol% TEMPO yield (%)a
ClZn SiMe2Ph
Br
Me
2.0 mol% NiBr2 •  diglyme
X mol% TEMPO
DMA /  THF
–20 °C, 2 h
Ar = p -anisyl
Ar
SiMe2Ph
MeAr
aYields were determined by GC analysis with the aid of a 
calibrated internal standard (average of two experiments).  
 
 S–17 
IV. References 
 
(1) Do, H.-Q.; Bachman, S.; Bissember, A. C.; Peters, J. C.; Fu, G. C. J. Am. Chem. Soc. 2014, 
136, 2162–2167.  
(2) Dudnik, A. S.; Fu, G. C. J. Am. Chem. Soc. 2012, 134, 10693–10697. 
(3) Procedure adapted from: Vyas, D. J.; Oestreich, M. Chem. Commun. 2010, 46, 568–570. 
(4) Kofron, W. G.; Baclawski, L. M. J. Org. Chem. 1976, 41, 1879–1880. 
(5) Krasovskiy, A.; Knochel, P. Synthesis 2006, 890−891. 
(6) Pai, Y.-M.; Wanek, E.; Weber, W. P. J. Organomet. Chem. 1984, 270, 271–275. 
(7) Nakamura, S.; Uchiyama, M. J. Am. Chem. Soc. 2007, 129, 28–29. 
(8) For a representative procedure, see Reference 7. 
 
 
0123456789
5.
51
0.
98
2.
92
1.
00
0.
99
0.
98
0.
98
2.
88
1.
84
1.
84
2.
70
1.
84
V.
  N
M
R 
Sp
ec
tra
 
S–
18
Me
SiMe2Ph
MeO
Table 2, Entry 1
1H NMR
(CDCl3, 500 MHz)
020406080100120140160180200
S–
19
Me
SiMe2Ph
MeO
Table 2, Entry 1
13C NMR
(CDCl3, 126 MHz)
0123456789
5.
65
4.
03
2.
92
2.
10
1.
00
2.
09
3.
09
1.
96
1.
93
2.
97
1.
99
S–
20
SiMe2Ph
MeO
Me
Me
Table 2, Entry 2
1H NMR
(CDCl3, 500 MHz)
020406080100120140160180200
S–
21
SiMe2Ph
MeO
Me
Me
Table 2, Entry 2
13C NMR
(CDCl3, 126 MHz)
0123456789
2.
79
2.
88
0.
96
8.
92
2.
28
1.
00
0.
99
2.
81
1.
92
1.
97
2.
93
1.
87
S–
22
Table 2, Entry 3
1H NMR
(CDCl3, 500 MHz)
SiMe2Ph
MeO
Me
Me Me
S–
23
Table 2, Entry 3
13C NMR
(CDCl3, 126 MHz)
SiMe2Ph
MeO
Me
Me Me
020406080100120140160180200
0123456789
5.
80
2.
96
0.
98
1.
01
1.
01
1.
01
1.
00
1.
96
0.
96
0.
92
2.
82
0.
96
2.
80
S–
24
O
CF3
Et
SiMe2Ph
Table 2, Entry 4
1H NMR
(CDCl3, 500 MHz)
S–
25
O
CF3
Et
SiMe2Ph
Table 2, Entry 4
13C NMR
(CDCl3, 126 MHz)
020406080100120140160180200
0123456789
5.
30
1.
00
2.
01
8.
55
1.
93
1.
83
1.
74
2.
59
1.
77
S–
26
N
SiMe2Ph
Boc
Table 2, Entry 5
1H NMR
(CDCl3, 500 MHz)
S–
27
N
SiMe2Ph
Boc
Table 2, Entry 5
13C NMR
(CDCl3, 126 MHz)
020406080100120140160180200
0123456789
5.
55
1.
10
2.
90
1.
38
1.
00
2.
87
1.
05
1.
01
2.
90
1.
89
2.
76
1.
80
S–
28
NPh
Me
Me
SiMe2Ph
Table 2, Entry 6
1H NMR
(CDCl3, 500 MHz)
S–
29
NPh
Me
Me
SiMe2Ph
Table 2, Entry 6
13C NMR
(CDCl3, 126 MHz)
020406080100120140160180200
0123456789
5.
82
4.
02
2.
98
3.
37
2.
10
1.
00
3.
03
3.
06
1.
19
2.
87
1.
95
S–
30
Table 2, Entry 7
1H NMR
(CDCl3, 500 MHz)
NSMe
O O
n-Bu
Me
SiMe2Ph
S–
31
Table 2, Entry 7
13C NMR
(CDCl3, 126 MHz)
NSMe
O O
n-Bu
Me
SiMe2Ph
020406080100120140160180200
S–
32
0123456789
5.
36
3.
61
1.
06
1.
02
1.
03
1.
00
1.
89
1.
71
1.
65
2.
85
1.
77
Cl
O Et
SiMe2Ph
Table 2, Entry 8
1H NMR
(CDCl3, 500 MHz)
S–
33
Cl
O Et
SiMe2Ph
Table 2, Entry 8
13C NMR
(CDCl3, 126 MHz)
020406080100120140160180200
S–
34
O
O Me
O SiMe2Ph
Table 2, Entry 9
1H NMR
(CDCl3, 500 MHz)
0123456789
5.
65
3.
87
1.
10
1.
00
2.
05
0.
91
0.
87
2.
80
1.
86
0.
86
S–
35
O
O Me
O SiMe2Ph
Table 2, Entry 9
13C NMR
(CDCl3, 126 MHz)
020406080100120140160180200
0123456789
5.
54
3.
97
1.
10
2.
05
0.
99
0.
96
1.
00
2.
78
0.
89
0.
93
0.
97
0.
94
2.
81
0.
92
1.
83
S–
36
Table 2, Entry 10
1H NMR
(CDCl3, 500 MHz)
N
Me
Et
SiMe2Ph
S–
37
Table 2, Entry 10
13C NMR
(CDCl3, 126 MHz)
N
Me
Et
SiMe2Ph
020406080100120140160180200
0123456789
5.
56
0.
98
2.
92
1.
00
1.
00
0.
98
0.
98
2.
85
1.
84
1.
84
2.
70
1.
84
S–
38
Me
SiMe2Ph
MeO
Eq 3
1H NMR
(CDCl3, 500 MHz)
S–
39
Me
SiMe2Ph
MeO
Eq 3
13C NMR
(CDCl3, 126 MHz)
020406080100120140160180200
0123456789
5.
89
5.
70
2.
14
2.
00
3.
25
2.
12
1.
96
3.
14
2.
00
S–
40
Table 3, Entry 1
1H NMR
(CDCl3, 500 MHz)
Me
SiMe2PhMe
MeO
S–
41
Table 3, Entry 1
13C NMR
(CDCl3, 126 MHz)
Me
SiMe2PhMe
MeO
020406080100120140160180200
0123456789
5.
62
9.
36
8.
34
2.
93
2.
00
S–
42
Table 3, Entry 2
1H NMR
(CDCl3, 500 MHz)
n-Pr SiMe2Ph
Me Me
S–
43
Table 3, Entry 2
13C NMR
(CDCl3, 126 MHz)
n-Pr SiMe2Ph
Me Me
020406080100120140160180200
S–
44
Table 3, Entry 3
1H NMR
(CDCl3, 500 MHz)
Me Me
SiMe2PhMe
Me
0123456789
6.
00
2.
71
3.
01
1.
35
1.
87
0.
91
3.
18
3.
27
2.
23
0.
98
3.
15
2.
17
020406080100120140160180200
S–
45
Table 3, Entry 3
13C NMR
(CDCl3, 126 MHz)
Me Me
SiMe2PhMe
Me
0123456789
5.
55
2.
93
6.
16
1.
93
1.
00
2.
95
1.
93
2.
76
1.
76
S–
46
Table 3, Entry 4
1H NMR
(CDCl3, 500 MHz)
n-Pentyl
SiMe2Ph
S–
47
Table 3, Entry 4
13C NMR
(CDCl3, 126 MHz)
n-Pentyl
SiMe2Ph
020406080100120140160180200
0123456789
5.
83
3.
00
1.
15
4.
48
3.
92
1.
31
2.
88
1.
99
S–
48
Table 3, Entry 5
1H NMR
(CDCl3, 500 MHz)
SiMe2Ph
Me
S–
49
Table 3, Entry 5
13C NMR
(CDCl3, 126 MHz)
SiMe2Ph
Me
020406080100120140160180200
0123456789
5.
65
2.
90
2.
01
2.
29
2.
07
2.
16
2.
00
3.
99
2.
89
1.
91
S–
50
Table 3, Entry 6
1H NMR
(CDCl3, 500 MHz)
O SiMe2Phn-Bu
020406080100120140160180200
S–
51
Table 3, Entry 6
13C NMR
(CDCl3, 126 MHz)
O SiMe2Phn-Bu
0123456789
5.
50
12
.0
0
2.
97
2.
68
1.
79
S–
52
SiMe2Ph
Eq 4
1H NMR
(CDCl3, 500 MHz)
S–
53
SiMe2Ph
Eq 4
13C NMR
(CDCl3, 126 MHz)
020406080100120140160180200
0123456789
2.
87
3.
06
1.
27
1.
13
1.
03
0.
99
1.
00
3.
03
1.
95
1.
92
5.
94
3.
88
S–
54
SiMePh2
Me
MeO
Eq 5
1H NMR
(CDCl3, 500 MHz)
S–
55
SiMePh2
Me
MeO
Eq 5
13C NMR
(CDCl3, 126 MHz)
020406080100120140160180200
0123456789
3.
04
1.
13
1.
11
1.
01
1.
08
1.
00
3.
17
2.
02
2.
03
6.
28
3.
27
6.
08
S–
56
SiPh3
Me
MeO
Eq 5
1H NMR
(CDCl3, 500 MHz)
S–
57
SiPh3
Me
MeO
Eq 5
13C NMR
(CDCl3, 126 MHz)
020406080100120140160180200
0123456789
2.
70
2.
81
0.
42
0.
41
0.
90
2.
00
2.
40
4.
29
0.
15
1.
81
0.
28
2.
95
1.
99
S–
58
SiMe2Ph
Eq 6
7:1 exo/endo
1H NMR
(CDCl3, 500 MHz)
S–
59
SiMe2Ph
Eq 6
7:1 exo/endo
13C NMR
(CDCl3, 126 MHz)
020406080100120140160180200
0123456789
2.
95
3.
03
0.
44
0.
44
0.
99
2.
17
2.
72
2.
43
2.
15
0.
16
2.
00
0.
31
3.
26
2.
19
S–
60
SiMe2Ph
Eq 7
7:1 exo/endo
1H NMR
(CDCl3, 500 MHz)
S–
61
SiMe2Ph
Eq 7
7:1 exo/endo
13C NMR
(CDCl3, 126 MHz)
020406080100120140160180200
